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Tofacitinib in Patients With Psoriatic Arthritis and 
Metabolic Syndrome: A Post hoc Analysis of Phase 3 
Studies
Christopher T. Ritchlin,1  Jon T. Giles,2 Alexis Ogdie,3  Juan J. Gomez-Reino,4 Philip Helliwell,5  
Pamela Young,6 Cunshan Wang,7 Joseph Wu,7 Ana Belén Romero,8 John Woolcott,6 and Lori Stockert6
Objective. Metabolic syndrome (MetS) is a cluster of concurrent risk factors for cardiovascular disease and type 2 
diabetes. This post hoc analysis explored key efficacy and safety endpoints in patients with psoriatic arthritis (PsA) 
and MetS treated with tofacitinib.
Methods. Tofacitinib 5 and 10 mg twice daily and placebo data were pooled from two Phase 3 studies (OPAL 
Broaden [12 months; ClinicalTrials.gov identifier NCT01877668]; OPAL Beyond [6 months; ClinicalTrials.gov identifier 
NCT01882439]); patients received one background conventional synthetic disease-modifying antirheumatic drug. 
Patients were stratified by baseline presence/absence of MetS. Efficacy and safety were reported to month 3 (tofacitinib 
and placebo) and 6 (tofacitinib only). Efficacy outcomes included: American College of Rheumatology (ACR)20/50/70, 
Health Assessment Questionnaire-Disability Index (HAQ-DI) response, Psoriasis Area Severity Index (PASI)75 
response, and enthesitis/dactylitis resolution rates; and changes from baseline (Δ) in C-reactive protein, HAQ-DI, 
Patient’s/Physician’s Global Assessment of Arthritis, and patient-reported outcomes. Safety outcomes included 
treatment-emergent all-causality adverse events (AEs), Δ in lipid/hepatic values, and liver parameter increases.
Results. Of 710 patients, 41.4% (n = 294) had baseline MetS. All efficacy outcomes improved with both tofacitinib 
doses versus placebo, to month 3; tofacitinib efficacy was consistent to month 6, regardless of MetS status. MetS 
did not appear to affect the incidence of AEs or Δ in lipid/hepatic values with tofacitinib up to month 3 or 6. Arterial 
thromboembolism and myocardial infarction (adjudicated major adverse cardiovascular events) were each reported 
once in tofacitinib-treated patients with MetS.
Conclusion. Regardless of baseline MetS status, tofacitinib showed greater efficacy versus placebo in patients 
with active PsA. The tofacitinib safety profile appeared similar in patients with versus without MetS.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, immune-mediated 
inflammatory musculoskeletal disorder associated with a high 
prevalence of metabolic syndrome (MetS) (1), a cluster of con-
current risk factors that can lead to higher incidence of cardio-
vascular (CV) disease and type 2 diabetes (2-4). According to a 
2009 international consensus statement, abnormal findings in at 
least three of five components (central obesity, elevated triglyc-
erides, reduced high-density lipoprotein [HDL]-cholesterol, ele-
vated blood pressure, and elevated fasting glucose) constitute 
MetS (2). As MetS and its components comprise CV risk fac-
tors, these patients should be identified clinically and managed 
accordingly.
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MetS is known to be associated with insulin resistance and 
chronic systemic inflammation (5). Central obesity, the most prev-
alent manifestation of MetS, may play a role in both, with excess 
adipose tissue resulting in higher levels of hormones and proin-
flammatory cytokines such as leptin, interleukin (IL)-6, and tumor 
necrosis factor (TNF)-α (5,6).
Elevated levels of leptin, IL-6, TNF-α, and other proinflam-
matory cytokines are also associated with inflammatory diseases, 
such as PsA (7,8); the prevalence of MetS is significantly higher in 
patients with PsA than in patients with noninflammatory muscu-
loskeletal disease (9), and the presence of MetS was associated 
with more severe PsA (1).
Of note, patients with both PsA and MetS are less likely to 
achieve minimal disease activity when treated with TNF-α inhibitors 
(TNFi), compared with TNFi-treated patients with PsA but without 
MetS (10). Furthermore, in a meta-analysis, obesity was associated 
with a decreased response to TNFi in patients with PsA (11).
Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treat-
ment of PsA. The efficacy and safety of tofacitinib 5 and 10 mg 
twice daily (BID) were demonstrated in two Phase 3 studies of up 
to 6 or 12 months’ duration in patients with PsA who had an inad-
equate response (IR) to csDMARDs or TNFi (12,13), and in a long-
term extension study (NCT01976364) (14). The impact of MetS 
on tofacitinib efficacy has not previously been assessed; however, 
a higher body mass index (BMI; ≥ 35 kg/m2) is associated with 
reduced tofacitinib response in patients with PsA (15).
The objective of this post hoc analysis was to compare key 
efficacy and safety endpoints in patients with PsA who were 
treated with tofacitinib in combination with a background csD-
MARD in the Phase 3 studies according to the presence or 
absence of comorbid MetS.
METHODS
Study design. This post hoc analysis included pooled data 
from two Phase 3 studies, the primary results of which have been 
reported elsewhere (12,13). OPAL Broaden (NCT01877668) and 
OPAL Beyond (NCT01882439) were randomized, double-blind, 
placebo-controlled studies that enrolled patients aged 18 years 
or older who were diagnosed with PsA (≥ 6 months; based on 
the ClASsification criteria for Psoriatic ARthritis [CASPAR] [24]), 
with active arthritis (≥ 3 swollen joints and ≥ 3 tender/painful joints 
on motion) at screening and baseline, and active plaque psoriasis 
at screening.
OPAL Broaden was a 12-month study that enrolled patients 
who had an IR to one or more csDMARD and had not previously 
received a TNFi (TNFi-naïve) (12). OPAL Beyond was a 6-month 
study that enrolled patients who had an IR to one or more TNFi 
(TNFi-IR) (13). Patients were randomized to receive tofacitinib 
5 mg BID, tofacitinib 10 mg BID, adalimumab 40 mg by sub-
cutaneous injection every other week (OPAL Broaden only), or 
placebo advancing to tofacitinib 5 or 10 mg BID at month 3. All 
patients in both studies continued on a stable dose of a single 
csDMARD.
Post hoc analysis. This post hoc analysis included all 
patients who received one or more dose of tofacitinib or placebo 
in OPAL Broaden and OPAL Beyond. For patients who were 
randomized to and received tofacitinib, data were pooled from 
both studies up to month 6. Patients who received placebo and 
switched to tofacitinib at month 3 were not included in analyses 
up to month 6. For patients who received placebo, data were 
pooled up to month 3 (end of placebo-controlled period). Patients 
who received adalimumab in OPAL Broaden were excluded from 
this analysis, as the objective of this analysis was to compare 
tofacitinib and placebo in data pooled from both studies, and 
adalimumab was not administered in OPAL Beyond. The studies 
were also analyzed separately to assess the tofacitinib efficacy 
in patients with PsA by prior TNFi experience (TNFi-naïve [OPAL 
Broaden] vs TNFi-IR [OPAL Beyond]) and MetS at baseline.
Efficacy endpoints at months 3 and 6, and safety endpoints 
to months 3 and 6, were analyzed according to the presence or 
absence of MetS at baseline. MetS was defined per previously 
standardized criteria (2).
Efficacy analysis. Efficacy assessments included the 
primary endpoints from OPAL Broaden and OPAL Beyond: the 
proportion of patients achieving an American College of Rheu-
matology (ACR)20 response (≥ 20% improvement from baseline 
in ACR components) (16) at month 3, and change from baseline 
to month 3 in Health Assessment Questionnaire-Disability Index 
(HAQ-DI; range: 0-3; higher scores indicate greater disability).
Further binary efficacy endpoints at months 3 and 6 include 
achievement of ACR20 (at month 6), ACR50, and ACR70 
(≥ 50% and ≥ 70% improvements from baseline in ACR compo-
nents, respectively) responses, achievement of HAQ-DI minimally 
clinically important response (reduction from baseline of ≥ 0.35 
points) (17) in patients with baseline HAQ-DI ≥ 0.35, ≥ 75% reduc-
tion from baseline Psoriasis Area and Severity Index (PASI75) 
response in patients with plaque psoriasis affecting ≥ 3% body 
surface area at baseline and a baseline PASI score > 0, enthesi-
tis resolution (using Leeds Enthesitis Index [LEI]) in patients with 
baseline LEI > 0, and dactylitis resolution (using Dactylitis Severity 
Score [DSS]) in patients with baseline DSS > 0.
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Additional continuous endpoints included change from 
baseline in HAQ-DI at month  6, and changes from baseline 
at months 3 and 6 in Physician’s Global Assessment of Arthri-
tis (PGA; measured by Visual Analog Scale [VAS], 0-100 mm), 
swollen joint count (SJC; 66 joints), tender/painful joint count 
(TJC; 68 joints), C-reactive protein (CRP; further stratification 
by baseline CRP levels ≤ 2.87 or > 2.87 mg/L), and patient-re-
ported outcomes (PROs), including Patient’s Global Assess-
ment of Arthritis (PtGA; VAS, 0-100 mm), Patient’s Assessment 
of Arthritis Pain (‘Pain’; VAS, 0-100 mm), Functional Assess-
ment of Chronic Illness Therapy-Fatigue (FACIT-F) total score, 
Short Form-36 Health Survey Acute Version 2 (SF-36v2; report-
ing component and norm-based domain scores) (18), and 
EuroQol 5-Dimensions 3-Level (EQ-5D-3L; reporting total and 
dimension scores) and EQ-VAS (mm; your own health state 
today) (19).
Statistical analysis of efficacy endpoints. For binary 
endpoints using pooled data from two studies, treatment differ-
ences (95% confidence interval [CI]) were analyzed using large 
sample approximation of the difference in binomial proportions 
using a Cochran-Mantel-Haenszel approach adjusting for study. 
Response rates (standard error [SE]) were reported by treat-
ment group and baseline MetS status, and treatment differences 
(95% CI) were calculated for tofacitinib doses versus placebo 
at month 3. A missing response was considered a nonresponse 
to treatment.
Continuous endpoints, except CRP, using pooled data 
from two studies, were analyzed using a mixed model for 
repeated measures, with fixed effects of treatment, visit, study, 
treatment-by-visit, baseline MetS, treatment-by-baseline MetS, 
visit-by-baseline MetS, treatment-by-visit-by-baseline MetS 
interactions, geographical region, and baseline value. Missing 
values were not imputed in the model. A common unstructured 
covariance matrix was used. Least squares (LS) mean changes 
from baseline were calculated at months 3 and 6 using two sep-
arate models. Results at month 3 were based on a model that 
included tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo 
treatment groups; as the placebo group was only included up 
to month 3 (end of placebo-controlled period), the results at month 
6 were based on a separate model that included only tofacitinib 
5 mg BID and tofacitinib 10 mg BID treatment groups. Treatment 
differences (95% CI) were calculated for tofacitinib doses versus 
placebo at month 3, by baseline MetS.
For analyses of efficacy endpoints performed by study (prior 
TNFi experience), similar methods were used as for pooled data, 
but without adjustment to study.
CRP data were pooled from the two studies. Mean (SE) 
change from baseline was calculated descriptively at months 3 
and 6, by treatment group, stratified by baseline MetS status and 
CRP cutoff (≤ 2.87 vs > 2.87 mg/L, where 2.87 mg/L is the upper 
limit of normal range).
Interaction analysis. To evaluate whether treatment 
effects were different between patients with and without baseline 
MetS, the interaction effects of baseline MetS status and treat-
ment group on ACR20/50 and PASI75 response, and on changes 
from baseline in HAQ-DI and CRP, were assessed at month 3. 
ACR20/50 and PASI75 responses were assessed using a multiple 
logistic regression model, and changes from baseline in HAQ-DI 
and CRP were assessed using an analysis of covariance model. 
Both models used fixed effects of treatment, baseline MetS, treat-
ment-by-baseline MetS, study, geographical region, age, and 
PsA disease duration. For assessments of interaction effects for 
ACR20/50 and PASI75, a missing response was considered a 
nonresponse; for HAQ-DI and CRP, patients with missing change 
from baseline values were excluded from the analysis. A value of 
P ≤ 0.05, based on Wald test of type 3 analysis for interaction 
effect, was considered statistically significant.
Safety analysis. Treatment-emergent all-causality adverse 
events (AEs) were reported up to months 3 and 6 by Medical Dic-
tionary for Regulatory Activities (MedDRA) Preferred Term. AEs of 
potential interest in patients with MetS, including fasting blood glu-
cose increase, hyperglycemia, diabetes, hypertension, and hepatic 
steatosis were analyzed descriptively. Major adverse cardiovascu-
lar events (MACE) were adjudicated by an external, independent 
committee. The following laboratory parameters were assessed 
at months 3 and 6: percent change from baseline in fasting lipid 
values (low-density lipoprotein [LDL]-cholesterol, HDL-cholesterol, 
total cholesterol, and triglycerides), change from baseline in hepatic 
laboratory values (total bilirubin, aspartate aminotransferase [AST], 
alanine aminotransferase [ALT], and gamma glutamyl transferase 
[GT]); and incidence of liver parameters as multiples of the upper 
limit of normal (ULN) (for total bilirubin, AST, ALT, and gamma GT). 
Change from baseline in hepatic values and incidence of liver 
parameters were assessed without regard for baseline abnormality.
RESULTS
Patients. Of the 710 patients in this pooled analysis, 294 
(41.4%) had baseline MetS (120 from OPAL Broaden; 174 from 
OPAL Beyond).
Demographics and baseline characteristics are summarized 
in Table 1. Across all treatment groups in both the pooled anal-
ysis and individual studies, patients with baseline MetS tended 
to be older with higher mean BMI versus patients without MetS. 
A greater proportion of patients with baseline MetS had abdom-
inal obesity, a CRP level > 2.87 mg/L, and were taking lipid-low-
ering medications at baseline, versus patients without baseline 
MetS. Baseline PRO values appeared similar regardless of base-
line MetS status (Table 1 and Online Supplementary Table 1). 
Baseline demographics, disease characteristics, and PRO values 
were generally similar among patients in each study, regardless of 
prior TNFi experience (Online Supplementary Table 2).
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Efficacy. Regardless of baseline MetS status, at month 3, 
the proportions of patients achieving ACR20/50/70, PASI75, and 
HAQ-DI response, as well as enthesitis and dactylitis resolution, 
were greater in patients receiving tofacitinib 5 or 10 mg BID ver-
sus placebo (Figure 1). This was supported by an analysis of the 
treatment differences between tofacitinib and placebo at month 
3 (Online Supplementary Figure 1), showing that response rates 
tended to be in favor of both tofacitinib doses versus placebo. 
Response rates were generally similar in patients with versus 
 without baseline MetS at months 3 and 6 (Figure 1); exceptions 
were HAQ-DI response with tofacitinib 10 mg BID at both time 
points, and dactylitis resolution at month 6 with both tofacitinib 
doses, which were lower in patients with versus without base-
line MetS. Among tofacitinib-treated patients, response rates 
were consistent up to month 6. Analyses of the interaction effects 
between treatment groups and baseline MetS status at month 3 
Table 1. Demographics and baseline disease characteristics by treatment group and baseline MetS status; pooled data from OPAL Broaden 
and OPAL Beyond
Tofacitinib 5 mg BIDa 
(N = 238)
Tofacitinib 10 mg BIDa 
(N = 236)
Placeboa 
(N = 236)
With 
baseline 
MetS 
(N = 99)
Without 
baseline 
MetS 
(N = 139)
With 
baseline 
MetS 
(N = 101)
Without 
baseline 
MetS 
(N = 135)
With 
baseline 
MetS 
(N = 94)
Without 
baseline 
MetS 
(N = 142)
OPAL Broadenb, N 38 69 36 68 46 59
OPAL Beyondc, N 61 70 65 67 48 83
Demographics
Age (y), mean (SD) 53.0 (11.0) 46.9 (12.8) 53.2 (10.4) 46.5 (11.9) 53.2 (11.4) 45.2 (12.2)
Female, n (%) 51 (51.5) 70 (50.4) 59 (58.4) 77 (57.0) 48 (51.1) 88 (62.0)
Race, n (%)
White 95 (96.0) 131 (94.2) 98 (97.0) 123 (91.1) 90 (95.7) 132 (93.0)
Other 4 (4.0) 8 (5.8) 3 (3.0) 12 (8.9) 4 (4.3) 10 (7.0)
BMI (kg/m2), mean (SD) 33.3 (6.1) 27.4 (5.4) 33.4 (5.7) 27.8 (5.5) 32.9 (4.8) 26.8 (4.8)
Abdominal obesityd, n (%) 88 (88.9) 63 (45.3) 93 (92.1) 54 (40.0) 86 (91.5) 54 (38.0)
Patients taking concomitant lipid-lowering 
medications at baselinee, n (%)
25 (25.3) 4 (2.9) 32 (31.7) 7 (5.2) 21 (22.3) 5 (3.5)
Disease characteristics
Psoriatic arthritis duration (y), mean (SD) 9.2 (7.9) 8.2 (7.9) 8.2 (6.5) 6.9 (6.6) 7.2 (6.3) 8.7 (8.2)
SJC (66), mean (SD) 13.6 (11.9) 11.6 (8.9) 14.2 (11.6) 10.9 (8.0) 11.8 (9.4) 10.4 (8.5)
TJC (68), mean (SD) 21.3 (13.4) 20.0 (12.4) 26.9 (17.5) 20.5 (13.9) 22.9 (14.9) 18.3 (14.2)
CRP (mg/L)
> 2.87f, n (%) 69 (69.7) 84 (60.4) 68 (67.3) 80 (59.3) 62 (66.0) 81 (57.0)
Mean (SD) 11.1 (18.5) 13.1 (21.9) 10.1 (16.3) 13.4 (25.2) 11.9 (18.4) 11.0 (21.4)
Median (range) 5.2 (0.2-126.0) 5.8 (0.2-115.0) 5.0 (0.4-100.0) 5.0 (0.2-163.0) 5.3 (0.3-100.0) 4.0 (0.2-164.0)
PASI, mean (SD)g 9.5 (7.5) 8.7 (8.1) 10.6 (8.5) 9.8 (7.4) 12.0 (11.7) 9.3 (8.5)
LEI, mean (SD)h 2.9 (1.6) 2.7 (1.5) 3.5 (1.7) 3.0 (1.7) 2.7 (1.5) 2.8 (1.5)
DSS, mean (SD)i 8.6 (8.7) 8.3 (9.3) 10.3 (9.9) 8.0 (6.4) 7.9 (6.0) 8.6 (8.0)
HAQ-DI, mean (SD) 1.3 (0.7) 1.2 (0.6) 1.4 (0.6) 1.2 (0.6) 1.3 (0.7) 1.1 (0.7)
PtGA (mm), mean (SD) 54.9 (22.8) 57.1 (22.4) 58.3 (21.2) 54.9 (23.6) 57.5 (23.7) 53.2 (22.9)
PGA (mm), mean (SD) 55.7 (20.0) 52.8 (20.3) 55.8 (20.1) 55.3 (18.0) 54.4 (19.0) 53.3 (21.0)
Pain (mm), mean (SD) 55.1 (22.7) 56.7 (24.1) 59.9 (19.0) 55.3 (24.0) 56.0 (24.7) 52.9 (24.3)
FACIT-F total score, mean (SD) 26.0 (11.4) 27.6 (11.5) 26.2 (10.6) 27.6 (10.3) 27.8 (10.6) 28.0 (10.8)
SF-36v2 PCS, mean (SD) 33.7 (7.8) 34.8 (8.5) 32.0 (8.7) 35.1 (8.4) 34.2 (8.4) 36.0 (8.8)
SF-36v2 MCS, mean (SD) 41.1 (12.7) 39.6 (11.1) 40.3 (12.0) 39.9 (12.3) 40.2 (11.9) 40.1 (11.7)
EQ-VAS (mm), mean (SD) 52.8 (21.7) 50.8 (22.2) 48.9 (21.6) 51.7 (20.3) 53.2 (22.8) 51.6 (19.5)
Abbreviations: BID, twice daily; BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; csDMARD, conventional synthetic disease-
modifying antirheumatic drug; DSS, Dactylitis Severity Score; EQ, EuroQol; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; 
HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; MCS, Mental Component Summary; MetS, metabolic 
syndrome; PASI, Psoriasis Area and Severity Index; PCS, Physical Component Summary; PGA, Physician’s Global Assessment of Arthritis; PtGA, 
Patient’s Global Assessment of Arthritis; SD, standard deviation; SF-36v2, Short Form-36 Health Survey Acute Version 2; SJC, swollen joint count 
(out of 66 joints); TJC, tender/painful joint count (out of 68 joints); TNFi, tumor necrosis factor inhibitor; VAS, Visual Analog Scale.
a  All patients received a stable dose of one background csDMARD.  
b  All patients had not previously received a TNFi, except one patient randomized to placebo who received etanercept prior to enrollment.  
c  All patients had an inadequate response to ≥ 1 TNFi.  
d  Based on elevated waist circumference; waist circumference thresholds are population- and country-specific (2).  
e  Baseline concomitant lipid-lowering medications were defined as drugs taken at baseline (Day 1).  
f  Upper limit of normal.  
g  PASI was assessed only in patients with baseline BSA ≥ 3% and PASI > 0.  
h  Baseline LEI was summarized only for patients with baseline LEI > 0.  
i  Baseline DSS was summarized only for patients with baseline DSS > 0.  
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demonstrated no significant interactions for ACR20 (P = 0.23), 
ACR50 (P = 0.93), and PASI75 (P = 0.92) response rates.
When prior TNFi experience was taken into account, response 
rates across all outcomes were generally similar within each treat-
ment group at months 3 and 6, irrespective of baseline MetS, and 
there were no clear trends between TNFi-naïve (OPAL Broaden) and 
TNFi-IR (OPAL Beyond) patients (Online Supplementary Figure 2); 
however, some small differences were observed. Compared with 
the pooled data and TNFi-IR patients, numerically higher response 
rates were observed in TNFi-naïve patients for ACR20 and ACR50 
responses at months 3 and 6 with tofacitinib 10 mg BID, and for 
PASI75 response at month 3 with tofacitinib 5 mg BID and at month 
6 for both tofacitinib doses. Enthesitis and dactylitis resolution rates 
appeared numerically more favorable in TNFi-IR patients receiving 
tofacitinib 5 mg BID at month 3 compared with the pooled data and 
TNFi-naïve patients.
Regardless of baseline MetS status, LS mean improve-
ments from baseline in disease-related measures and PROs were 
greater with both tofacitinib doses versus placebo at month 3; 
improvements observed with tofacitinib were consistent to month 
6 (Figure 2A–E; Online Supplementary Figure 3), and treatment dif-
ferences at month 3 were in favor of either tofacitinib dose versus 
placebo (Online Supplementary Figure 4). In patients with elevated 
CRP levels at baseline, mean reductions from baseline in CRP 
were similar in tofacitinib-treated patients irrespective of baseline 
MetS status; except at month 3 in the tofacitinib 10 mg BID group, 
when patients with MetS experienced less pronounced reductions 
in CRP versus those without MetS (Figure 2F). In patients with 
Figure 1. Response rate (SE) for ACR20 (A), ACR50 (B), ACR70 (C), PASI75a (D), and HAQ-DI responseb (E), enthesitis resolutionc (F) and 
dactylitis resolutiond (G) rates at months 3 and 6, by treatment group and baseline MetS status; pooled data from OPAL Broaden and OPAL 
Beyond. aPASI was assessed only in patients with baseline BSA ≥ 3% and PASI > 0. bHAQ-DI response is defined as a decrease ≥ 0.35 among 
patients with baseline HAQ-DI score ≥ 0.35. cEnthesitis resolution was assessed only in patients with baseline LEI > 0. dDactylitis resolution was 
assessed only in patients with baseline DSS > 0. A patient with a missing value was considered a nonresponder. Abbreviations: ACR, American 
College of Rheumatology; BID, twice daily; BSA, body surface area; DSS, Dactylitis Severity Score; HAQ-DI, Health Assessment Questionnaire-
Disability Index; LEI, Leeds Enthesitis Index; MetS, metabolic syndrome; N, number of patients with nonmissing baseline MetS; PASI, Psoriasis 
Area and Severity Index; SE, standard error.
(A) (B)
(C) (D)
(E)
(G)
(F)
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baseline CRP ≤ 2.87 mg/L who received either dose of tofacitinib, 
CRP levels increased at month 3 in patients with baseline MetS, 
and remained stable in patients without MetS.
Interaction analyses of baseline MetS status and treatment 
group also demonstrated no significant interaction on change 
from baseline in HAQ-DI (P = 0.89) and CRP (P = 0.18) at month 3.
LS mean improvements from baseline in LEI, DSS, HAQ-DI, 
PGA, PtGA, Pain, SJC, TJC, and CRP with tofacitinib were gen-
erally comparable at months 3 and 6, regardless of prior TNFi 
experience and baseline MetS (Online Supplementary Figures 5 
and 6).
LS mean improvements from baseline in SF-36v2 (espe-
cially bodily pain), EQ-VAS, and EQ-5D-3L pain/discomfort score 
were greater with both tofacitinib doses versus placebo, both in 
patients with and without baseline MetS (Online Supplementary 
Figures 7 and 8).
Safety. The proportions of patients with treatment-emer-
gent AEs, serious AEs, and AEs leading to discontinuations were 
generally similar between patients with and without MetS receiv-
ing tofacitinib 5 mg BID, tofacitinib 10 mg BID, or placebo up 
to months 3 and 6 (Table 2).
The most common AEs reported in ≥ 5% of patients 
(Online Supplementary Table 3) up to month 3 were gener-
ally similar across treatment groups: nasopharyngitis, upper 
respiratory tract infection, headache, and diarrhea. Additional 
commonly reported AEs up to month 6 were: bronchitis, lower 
respiratory tract infection, urinary tract infection, and hyper-
tension. No clear trends in AEs were observed based on 
baseline MetS status. There also did not appear to be a clear 
trend in AEs potentially associated with MetS (Table 3). One 
patient with baseline MetS who received tofacitinib 5 mg BID 
up to month 3, experienced an arterial thromboembolic event 
Figure 2. LS mean (SE) change from baseline in HAQ-DI (A), PGA (VAS, mm) (B), PtGA (VAS, mm) (C), Pain (VAS, mm) (D), and FACIT-F total 
score (E) at months 3 and 6 by treatment group and baseline MetS status, and mean (SE) change from baseline in CRP (F), at months 3 and 6, by 
treatment group, baseline MetS status, and baseline CRP ≤ 2.87 mg/L and > 2.87 mg/L; pooled data from OPAL Broaden and OPAL Beyond. Each 
of the endpoints (except CRP) were analyzed using a mixed model for repeated measures, with fixed effects of treatment, visit, study, treatment-
by-visit, baseline MetS, treatment-by-baseline MetS, visit-by-baseline MetS, treatment-by-visit-by-baseline MetS interactions, geographical region, 
and baseline value. Missing values were not imputed. A common unstructured covariance matrix was used. LS mean (SE) changes from baseline 
were calculated at months 3 and 6 using two separate models. Results at month 3 were based on a model that included tofacitinib 5 mg BID, 
tofacitinib 10 mg BID, and placebo treatment groups; as the placebo treatment group was only included up to month 3 (end of placebo-controlled 
period), the results at month 6 were based on a separate model that included only tofacitinib 5 mg BID and tofacitinib 10 mg BID treatment groups. 
Arithmetic mean (SE) was calculated for change from baseline in CRP by treatment group, baseline MetS status, and CRP cutoff. Abbreviations: Δ, 
change from baseline; BID, twice daily; CRP, C-reactive protein; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health 
Assessment Questionnaire-Disability Index; LS mean, least squares mean; MetS, metabolic syndrome; N, number of patients evaluable at months 3 
and 6; PtGA, Patient’s Global Assessment of Arthritis; PGA, Physician’s Global Assessment of Arthritis; SE, standard error; VAS, Visual Analog Scale.
(A)
(C) (D)
(E) (F)
(B)
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(day 45; the MedDRA Preferred Term was amaurosis fugax; 
this was adjudicated as a transient ischemic attack); the treat-
ment was stopped temporarily, and the AE was resolved. One 
patient with baseline MetS who received tofacitinib 5 mg BID 
up to month 6 (last day of tofacitinib treatment was day 169) 
experienced an acute myocardial infarction on day 245, which 
was adjudicated as a MACE.
At baseline, LDL-cholesterol, total cholesterol, and triglyc-
eride levels were higher, and HDL-cholesterol levels were lower, 
in patients with baseline MetS versus without MetS (Table 4), 
as expected. Regardless of baseline MetS status, mean per-
cent changes from baseline in fasting lipid values were greater 
with either tofacitinib dose versus placebo up to month 3, 
and results were consistent to month 6; tofacitinib 10 mg 
BID-treated patients without baseline MetS experienced a 
substantially greater change in triglyceride levels versus other 
patient groups (Table 4). Between baseline and month 3, eight 
patients with baseline MetS began lipid-lowering medications 
(tofacitinib 5 mg BID, n = 1 [1.0%]; tofacitinib 10 mg BID, n = 5 
[5.0%]; placebo, n = 2 [2.1%]); two patients without baseline 
MetS began lipid-lowering medications (tofacitinib 5 mg BID, 
n = 1 [0.7%]; tofacitinib 10 mg BID, n = 1 [0.7%]).
At baseline, total bilirubin (for tofacitinib 5 mg BID only), 
AST, ALT, and gamma GT values were generally slightly higher 
in patients with versus without baseline MetS (Online Sup-
plementary Table 4). In tofacitinib-treated patients, AST and 
ALT levels slightly increased from baseline, and to a greater 
extent in those with MetS versus those without MetS (Online 
Supplementary Table 4). No clear pattern in the proportions 
of patients with liver parameters above ULN thresholds was 
observed between those with or without MetS (Online Supple-
mentary Table 5).
DISCUSSION
This analysis compared the efficacy and safety of tofac-
itinib in patients with PsA, stratified by baseline MetS status. 
Regardless of baseline MetS status, tofacitinib 5 or 10 mg BID 
tended to show greater efficacy than placebo at month 3 in 
patients with active PsA, across all endpoints (ACR20/50/70, 
PASI75, HAQ-DI response, enthesitis and dactylitis resolution, 
and changes from baseline in HAQ-DI, PGA, SJC, TJC, CRP 
[in patients with baseline CRP > 2.87 mg/L], and additional 
PROs). These improvements were consistent to month 6 with 
tofacitinib. Additionally, baseline MetS status did not appear 
to affect tofacitinib safety up to month 3 or 6, as assessed by 
AEs, serious AEs, discontinuations due to AEs, and changes in 
lipid or liver parameters.
The efficacy of tofacitinib generally appeared unaffected by 
baseline MetS status at months 3 and 6, although some differ-
ences were noted in HAQ-DI response at both time points with 
tofacitinib 10 mg BID, and dactylitis resolution with both tofacitinib 
doses at month 6. In patients with baseline CRP > 2.87 mg/L, 
CRP decrease from baseline with tofacitinib 10 mg BID appeared 
lower at month 3 in patients with baseline MetS versus those with-
out baseline MetS; however, the reason for this remains unclear. 
The reduction in CRP levels observed with tofacitinib may relate 
to its downstream effect on IL-6, which influences CRP levels 
(5). Although BMI has previously been reported to be positively 
correlated with CRP levels in PsA patients (20,21), in this anal-
ysis, baseline CRP levels appeared similar in patients with and 
without baseline MetS, despite patients with baseline MetS hav-
ing a higher baseline BMI. Additionally, at month 3, there was no 
interaction between treatment group, baseline MetS status, and 
efficacy endpoints, suggesting that baseline MetS status does not 
Table 2. Treatment-emergent adverse events up to months 3 and 6; pooled data from OPAL Broaden and OPAL 
Beyond
Tofacitinib 5 mg BIDa 
(N = 238)
Tofacitinib 10 mg BIDa 
(N = 236)
Placeboa,b 
(N = 236)
n (%)
With 
baseline 
MetS 
(N = 99)
Without 
baseline 
MetS 
(N = 139)
With 
baseline 
MetS 
(N = 101)
Without 
baseline 
MetS 
(N = 135)
With 
baseline 
MetS 
(N = 94)
Without 
baseline 
MetS 
(N = 142)
Adverse events
Up to month 3 55 (55.6) 59 (42.4) 43 (42.6) 74 (54.8) 36 (38.3) 59 (41.5)
Up to month 6 68 (68.7) 86 (61.9) 67 (66.3) 92 (68.1) NA NA
Serious adverse events
Up to month 3 2 (2.0) 2 (1.4) 2 (2.0) 2 (1.5) 3 (3.2) 1 (0.7)
Up to month 6 4 (4.0) 6 (4.3) 5 (5.0) 6 (4.4) NA NA
Adverse events leading to  
discontinuation
Up to month 3 2 (2.0) 3 (2.2) 5 (5.0) 5 (3.7) 3 (3.2) 3 (2.1)
Up to month 6 3 (3.0) 7 (5.0) 8 (7.9) 6 (4.4) NA NA
Abbreviations: BID, twice daily; csDMARD, conventional synthetic disease-modifying antirheumatic drug; MetS, 
metabolic syndrome; N, number of patients analyzed; n, number of patients with the adverse event of interest; 
NA, not applicable.
a  All patients received a stable dose of one background csDMARD.  
b  Patients in the placebo group were advanced to tofacitinib 5 or 10 mg BID after 3 months of placebo treatment.  
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affect the treatment effects of tofacitinib doses differentially in PsA 
patients. Previous observations showing diminished responses to 
TNFi in patients with MetS or obesity (10,11) were not observed 
here with tofacitinib.
Limited data are available assessing the effect of MetS on 
PsA treatment efficacy. A previous study of TNFi treatment in 
patients with PsA and MetS determined that those with MetS 
were less likely to achieve minimal disease activity (10). Higher 
BMI has also previously been associated with reduced treatment 
response in patients with PsA receiving tofacitinib (15) and TNFi 
(11). In contrast, the current analysis demonstrated that, with the 
exception of the endpoints discussed above, tofacitinib efficacy 
across clinical outcomes and PROs appeared similar in patients 
regardless of baseline MetS status and were also generally con-
sistent with those seen in the OPAL Broaden and OPAL Beyond 
patient populations (12,13). Tofacitinib efficacy generally did not 
appear to be affected by prior TNFi experience, although for some 
outcomes (ACR20, ACR50, and PASI75 response rates), the 
tofacitinib 10 mg BID dose appeared to result in numerically bet-
ter responses in TNFi-naïve versus TNFi-IR patients, regardless of 
baseline MetS status; however, the variations may be due to the 
low patient numbers. The discrepancy in sample size between 
patients with versus without MetS in OPAL Broaden, and in some 
outcomes in OPAL Beyond, may also have impacted response 
rates. The elevated levels of TNF-α and IL-6 in patients with 
MetS may attenuate the efficacy of TNFi (10) to a greater extent 
than that of tofacitinib, which acts on the JAK-STAT pathway and 
downregulates the levels of multiple cytokines involved in PsA (eg, 
IL-2, IL-6, IL-17, IL-22, and IL-23) (7,22-25).
The safety profile of tofacitinib 5 and 10 mg BID was gen-
erally similar in patients with or without baseline MetS. Additional 
safety outcomes potentially important in the context of MetS (eg, 
fasting blood glucose levels, diabetes, and hypertension) were 
similar between treatment groups, and no new safety risks were 
identified, based on baseline MetS status (12,13). One event each 
of arterial thromboembolism and myocardial infarction occurred 
in tofacitinib-treated patients with baseline MetS. AEs of spe-
cial interest (ie, herpes zoster, serious infections, opportunistic 
infections, gastrointestinal perforations, interstitial lung disease, 
and malignancies) have been reported previously (12,13) and were 
not assessed in this analysis due to the low number of patients 
with these events in the index studies, which limits meaningful 
interpretation when analyzed further by baseline MetS subgroup. 
In tofacitinib-treated patients, HDL-cholesterol, LDL-cholesterol, 
and triglyceride elevations at month 3 were similar to the index 
studies regardless of baseline MetS status. A pooled analysis of 
the OPAL Broaden and OPAL Beyond studies in patients with 
active PsA observed dose-dependent increases in lipid levels of 
10% to 15% following treatment with tofacitinib 5 and 10 mg BID 
at month 3, with no appreciable changes at month 6 (26). Rel-
evant prescribing information recommends that lipid parameters 
are assessed between 4 and 8 weeks (US prescribing information) 
or 8 weeks (European Union summary of product characteristics) 
after tofacitinib initiation, and that patients are managed accord-
ing to clinical guidelines (27,28). The above pooled analysis also 
found that across OPAL Broaden, OPAL Beyond, and a long-term 
extension study (median duration of tofacitinib exposure 594.0 
days; range 1-1,196 days), tofacitinib did not affect hypertension 
rates, CRP levels decreased, and the incidence of MACE was low 
(26). However, MACE have a long latency, and an ongoing ran-
domized comparator study in rheumatoid arthritis is specifically 
investigating the risk of MACE with tofacitinib (ClinicalTrials.gov 
identifier NCT02092467). At month 3, slightly greater numerical 
increases from baseline in AST and ALT were generally observed 
in patients with baseline MetS versus those without baseline MetS. 
Given that MetS is a strong predictor of nonalcoholic fatty liver 
disease (29), there may also be a potential hepatic impact in this 
patient population, but observed increases were generally small 
and remained stable, and were not clinically relevant up to month 
6. Routine monitoring of laboratory parameters, including liver 
enzymes, is recommended in patients treated with tofacitinib (28).
This post hoc analysis has limitations, and results should 
be interpreted with caution. Statistical analysis was estimation 
in nature, rather than hypothesis testing, with small patient 
numbers limiting potential conclusions, including comparisons 
between tofacitinib dose groups; furthermore, treatment differ-
ences between tofacitinib versus placebo, rather than patients 
with versus without MetS were assessed. Additionally, no univer-
sal consensus has been established for the diagnosis of MetS 
(30,31); the criteria applied here were based upon a consen-
sus statement from organizations that include the International 
Diabetes Federation and the National Heart, Lung, and Blood 
Institute (2). Therefore, these criteria may not fully capture the 
concepts of MetS impact on tofacitinib efficacy and safety in 
patients with PsA and MetS. Finally, it is also not known whether 
the lipid-lowering medications initiated after baseline were pre-
scribed due to tofacitinib therapy (as increases in lipid values 
after tofacitinib initiation have previously been observed) (32) or 
baseline MetS status.
In patients with active PsA, greater efficacy improvements 
were observed in patients who received tofacitinib 5 or 10 mg BID 
versus placebo, regardless of baseline MetS status. Additionally, 
MetS did not appear to affect the tofacitinib safety profile. Tofacitinib 
provides a treatment option for patients with active PsA, regardless 
of comorbid MetS. Future analyses of observational registry and/or 
clinical data will further inform the potential impact of MetS on the 
efficacy and safety of tofacitinib in patients with PsA.
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